Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., … Seymour, L. (2023). Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Annals of Oncology, 34(1), 48–60. https://doi.org/10.1016/j.annonc.2022.09.158
Authors:
D Araujo
A Greystoke
S Bates
A Bayle
E Calvo
L Castelo-Branco
J de Bono
A Drilon
E Garralda
P Ivy
O Kholmanskikh
I Melero
G Pentheroudakis
J Petrie
R Plummer
S Ponce
S Postel-Vinay
L Siu
A Spreafico
A Stathis
N Steeghs
C Yap
T A Yap
M Ratain
L Seymour
Affiliated Authors:
S Bates
Subjects:
Author Keywords:
project optimus
rp2d
dose optimization
phase i
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2022.09.158
PMID:
Publication Date:
Data Source:
PubMed

Record Created: